Literature DB >> 2958193

Origin of defective T lymphocyte-suppressor activating factor interaction in patients with rheumatoid arthritis.

E C Keystone1, S Budz-Tymkewycz, M Toews, C Lau.   

Abstract

We previously examined the generation of T cell released suppressor activity (TRSA) from peripheral blood T cells from patients with rheumatoid arthritis (RA) in response to a soluble suppressor activating factor (SAF) produced by a 6-thioguanine resistant mutant of the human T cell line CEM. We reported (Lau et al., 1985 Clin. exp. Immunol. 61, 481) that T cells from a substantial proportion of RA patients exhibited impaired TRSA release. To delineate further the TRSA abnormality observed in patients with active RA, we evaluated the kinetics of SAF activation, precursor frequency of SAF reactive cells and quantity of activated SAF released on a per cell basis. The results showed that a lower precursor frequency of SAF reactive cells accounted for defective TRSA release in a majority of RA patients, while TRSA release on a per cell basis was normal. The defective TRSA response to SAF could not be explained by abnormal dose kinetics of SAF, time kinetics of TRSA release or prior in vivo lymphocyte activation of the RA T cells.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2958193      PMCID: PMC1542242     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  12 in total

1.  Quantitative studies on the precursors of cytotoxic lymphocytes. I. Characterization of a clonal assay and determination of the size of clones derived from single precursors.

Authors:  H S Teh; E Harley; R A Phillips; R G Miller
Journal:  J Immunol       Date:  1977-03       Impact factor: 5.422

2.  A mutant human T-cell line producing immunosuppressive factor(s).

Authors:  C Y Lau; S Budz-Tymkewycz; E Y Wang; A Ishaque
Journal:  Cell Immunol       Date:  1984-08       Impact factor: 4.868

3.  Analysis of suppressor T cell function in patients with rheumatoid arthritis: defects in production of and responsiveness to concanavalin A-induced suppressor T cells.

Authors:  T Sakane; S Takada; Y Murakawa; H Kotani; M Honda; Y Ueda
Journal:  J Immunol       Date:  1982-11       Impact factor: 5.422

4.  Suppressor T cell dysfunction and anti-suppressor cell antibody in active early rheumatoid arthritis.

Authors:  N I Abdou; H B Lindsley; L S Racela; E Pascual; K M Hassanein
Journal:  J Rheumatol       Date:  1981 Jan-Feb       Impact factor: 4.666

5.  Evidence for activated peripheral blood T-cells in rheumatoid arthritis.

Authors:  E C Keystone; A Shore; R G Miller; P Tan; L Poplonski; P Leary; S Albert
Journal:  J Rheumatol Suppl       Date:  1983-12

6.  Synovial fluid lymphocytes differ from peripheral blood lymphocytes in patients with rheumatoid arthritis.

Authors:  R I Fox; S Fong; N Sabharwal; S A Carstens; P C Kung; J H Vaughan
Journal:  J Immunol       Date:  1982-01       Impact factor: 5.422

7.  Impaired release of a T-cell specific suppressor factor in rheumatoid arthritis.

Authors:  C Lau; S Budz-Tymkewycz; M Ramsden; P Lee; E C Keystone
Journal:  Clin Exp Immunol       Date:  1985-09       Impact factor: 4.330

8.  Analysis of T cell subsets in the peripheral blood and synovial fluid of patients with rheumatoid arthritis by means of monoclonal antibodies.

Authors:  O Duke; G S Panayi; G Janossy; L W Poulter; N Tidman
Journal:  Ann Rheum Dis       Date:  1983-08       Impact factor: 19.103

9.  Mechanism of action of a suppressor-activating factor (SAF) produced by a human T cell line.

Authors:  C Y Lau; E Y Wang; D Li; S Budz-Tymkewycz; V Visconti; A Ishaque
Journal:  J Immunol       Date:  1985-05       Impact factor: 5.422

10.  Graft-versus-host disease in murine bone marrow transplantation. II. Modulation of acute and chronic GVHD in mice receiving bone marrow allografts pretreated with immunosuppressive factor derived from a human T cell line.

Authors:  R M Gorczynski; C Y Lau; M Robillard
Journal:  Immunol Lett       Date:  1985       Impact factor: 3.685

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.